Share useful research with your peers
in · Share on LinkedIn ↗
COMPANY RESEARCH

Chime Biologics

鼎康生物 (Chime Biologics) offers Biologics analytical development, characterization, release and stability. This is the analytical service business of an integrated CRO/CDMO.

Company at a glance

Corporate information

Company entity
鼎康生物 (Chime Biologics)
Headquarters / principal office
Wuhan, China ↗ ↗ ↗ ↗ ↗ ↗ ↗ ↗ ↗ ↗ ↗
Founded
2013 ↗ ↗ ↗ ↗ ↗ ↗ ↗ ↗ ↗ ↗ ↗
Ownership / capital status
Not verifiedCapital status not fully verified
Official corporate reference
https://chimebiologics.com/ ↗
LinkedIn company page
Independent company page not verified

Profile review: 2026-11-05 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.

Disease tags match recorded text mentions and require program-level verification.

Technology, programs & evidence

Biologics analytical development, characterization, release and stability

Integrated CRO/CDMO analytical services

Individual program detail is not recorded. Consult the original sources below.

Related news & literature

Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.

No cataloged update explicitly mentions this company.

Same-field reading (not company-specific)
Communications Chemistry

Direct-infusion method accelerates antibody peptide mapping in a peer-reviewed study

A Communications Chemistry study reports RaPiD-mAb-MS, combining plate-based preparation with direct-infusion mass spectrometry for antibody peptide mapping. The original abstract describes analysis of 96 samples in about 1.5–2 hours, routinely exceeding 95% sequence coverage, across 28 antibodies and more than 2,000 samples. The reported comparisons cover several modifications and sequence variants; broader method suitability still requires evaluation.

U.S. Food and Drug Administration

FDA finalizes lifecycle potency assurance guidance for cell and gene therapies

FDA announced final guidance on potency assurance for cellular and gene therapies on November 2. Its recommendations integrate manufacturing-process design, material and process controls, in-process testing, and lot-release potency assays. The agency emphasizes product-specific, risk-based strategies across development and commercialization; this is final guidance, not approval of any individual therapy.

mAbs

Setting expectations for current and future directions of native mass spectrometry in the biopharmaceutical industry

This industry perspective examines native mass spectrometry as a complement to established biopharmaceutical characterization methods. It discusses intact assemblies, binding, stoichiometry, and heterogeneity, while identifying throughput, sensitivity, automation, and access limitations. The authors emphasize integration with analytical workflows rather than universal replacement of existing methods.

Research this company together

Discussions are for signed-in members. Personal notes remain separate from company research.

Sign in to join

Sources & open questions

  • Service-provider record; no proprietary drug pipeline implied. Confirm laboratory qualification and project suitability.
  1. Chime Biologics HomePage ↗鼎康生物 (Chime Biologics) ·
  2. 鼎康生物 (Chime Biologics) official disclosure ↗鼎康生物 (Chime Biologics) ·
  3. Privacy Policy ↗鼎康生物 (Chime Biologics) ·
  4. 隐私声明 ↗鼎康生物 (Chime Biologics) ·
  5. (English) Chime Biologics GMP-2 Opening and KuBio 10th Anniversary ↗鼎康生物 (Chime Biologics) ·
  6. Chime Biologics Evolving Into One of the Leading CDMOs in China Serving the Global Biotech Industry ↗鼎康生物 (Chime Biologics) ·
  7. Our Story ↗鼎康生物 (Chime Biologics) ·
  8. (English) Chime Biologics Announces the Establishment of Chime Alumni Association and Upcoming Chime Alumni Day Event ↗鼎康生物 (Chime Biologics) ·
  9. Our Team ↗鼎康生物 (Chime Biologics) ·
  10. Global Supply ↗鼎康生物 (Chime Biologics) ·
  11. Chime Biologics Announced the Expansion of GMP Manufacturing Capacity with Construction of a Second GMP Facility (GMP-2) ↗鼎康生物 (Chime Biologics) ·

Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.

AI assistant ↗